In a menopausal woman with a pacemaker, receiving oral psoralen‑UVA (PUVA) therapy for lichen planus and taking antithyroid medication (25 µg), what is the appropriate workup and management for her anemia and thrombocytopenia?

Workup and Management for Anemia and Thrombocytopenia in This Patient

In this menopausal woman with lichen planus on PUVA therapy, prioritize evaluation for iron deficiency anemia first (checking ferritin with a threshold of 45 mg/dL), followed by assessment for immune thrombocytopenia if platelet count is <30 × 10⁹/L, while recognizing that her lichen planus itself is strongly associated with hematinic deficiencies.

Initial Workup Algorithm

For Anemia Assessment:

Start with ferritin level using 45 mg/dL as the diagnostic threshold for iron deficiency 1. In this postmenopausal woman without GI bleeding history, the anemia workup should focus on:

• Complete blood count with MCV to classify the anemia type
• Serum ferritin (primary screening test)
• Serum iron, vitamin B12, and folic acid levels - particularly important because lichen planus patients have significantly higher frequencies of these deficiencies 2, 3
• Serum homocysteine level - elevated in 21.1% of OLP patients 2
• Gastric parietal cell antibody (GPCA) - positive in approximately 20% of OLP patients and may indicate autoimmune gastritis affecting B12 absorption 3

Critical context: Research shows that 25.2% of OLP patients have anemia, 16.8% have iron deficiency, 10.2% have vitamin B12 deficiency, and 1.2% have folic acid deficiency 2. Even in OLP patients with normocytosis (normal MCV), 14.3% still have anemia and 12.7% have iron deficiency 3.

For Thrombocytopenia Assessment:

If platelet count is documented as low, evaluate for:

• Platelet count confirmation with peripheral smear to exclude pseudothrombocytopenia
• Severity classification: <30 × 10⁹/L requires more aggressive consideration
• Bleeding assessment: mucocutaneous bleeding vs asymptomatic
• Medication review: thyroid medication at 25 mcg is unlikely culprit, but PUVA therapy should be considered

Management Strategy

For Iron Deficiency Anemia:

Begin oral iron supplementation as first-line therapy unless contraindicated 1:

• Ferrous sulfate, ferrous fumarate, or ferrous gluconate are reasonable first choices due to cost-effectiveness
• Dosing strategy: Take on empty stomach for optimal absorption, though taking with meals improves tolerance
• Absorption enhancement: Co-administer with 500 mg vitamin C and/or meat protein to improve absorption even with dietary calcium or fiber 1
• Alternative formulations: Consider ferrous bisglycinate if standard ferrous salts are poorly tolerated

Switch to IV iron if:

• Oral iron is not tolerated due to GI side effects (nausea, abdominal pain, constipation)
• Severe iron deficiency at presentation
• Iron stores fail to improve with oral supplementation 1

For Vitamin B12 or Folic Acid Deficiency:

• Oral supplementation is appropriate for most cases
• If GPCA positive: Consider higher B12 doses or parenteral administration due to impaired intrinsic factor-mediated absorption
• Monitor response with repeat hemoglobin and hematinic levels

For Thrombocytopenia (if platelet count <30 × 10⁹/L):

If asymptomatic or minor mucocutaneous bleeding only:

• Observation is reasonable as first approach 4
• Corticosteroids are suggested over observation per ASH guidelines, though this is a conditional recommendation based on very low certainty evidence 4

If symptomatic or significant bleeding:

• Corticosteroids as first-line therapy
• IV immunoglobulin for more urgent situations
• Avoid anti-D immunoglobulin in this patient (requires intact spleen and Rh-positive status)

Critical Medication Considerations

Pacemaker Interaction:

The pacemaker itself does not directly affect anemia or thrombocytopenia workup. However, avoid propranolol or other beta-blockers if being considered for any reason, as the drug label warns about severe bradycardia in pacemaker patients 5.

Antithyroid Medication:

At 25 mcg (likely levothyroxine for hypothyroidism rather than antithyroid medication), this dose is standard replacement therapy and unlikely to cause hematologic abnormalities. However, monitor thyroid function as beta-blockade can mask hyperthyroidism symptoms if thyroid status changes 5.

PUVA Therapy:

Continue PUVA for lichen planus management 6, 7 unless thrombocytopenia becomes severe enough to risk photosensitivity-related complications. PUVA is not a common cause of cytopenias.

Common Pitfalls to Avoid

• Don't assume normal MCV excludes iron deficiency: 12.7% of normocytic OLP patients still have iron deficiency 3
• Don't overlook multiple hematinic deficiencies: OLP patients frequently have combined deficiencies requiring simultaneous correction 2
• Don't use ferritin >45 mg/dL to exclude iron deficiency if inflammatory conditions present: Use transferrin saturation or soluble transferrin receptor for confirmation 1
• Don't routinely withdraw medications before addressing the underlying deficiencies: Focus on repletion first

Follow-up Monitoring

• Recheck CBC and hematinic levels at 4-8 weeks after starting supplementation
• Target hemoglobin normalization and ferritin >50 mg/dL for adequate iron stores
• If no improvement: Consider GI evaluation for malabsorption (celiac disease, H. pylori, atrophic gastritis) or occult bleeding source 1
• Platelet monitoring if thrombocytopenia confirmed, with frequency based on severity and bleeding risk